{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=3", "query": { "intervention": "Carbohydrate 50%", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 733, "total_pages": 74, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Carbohydrate+50%25&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T13:30:32.611Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06081543", "title": "Ketogenic Diet vs Mixed Diet in Patients With Heart Failure", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Heart Failure With Preserved Ejection Fraction" ], "interventions": [ { "name": "Ketogenic diet", "type": "DIETARY_SUPPLEMENT" }, { "name": "Low-fat Mixed diet", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Ohio State University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 90, "start_date": "2023-05-19", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06081543" }, { "nct_id": "NCT03835767", "title": "Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Milk and/or Peanut Allergy" ], "interventions": [ { "name": "Peanut powder and Oat flour", "type": "OTHER" }, { "name": "Peanut flour and Oat flour (placebo for peanut flour)", "type": "OTHER" }, { "name": "Dry Milk Powder and Corn Starch (placebo for Milk powder)", "type": "OTHER" }, { "name": "Baked milk and Rice milk (placebo for Baked milk)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 200, "start_date": "2019-04-19", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03835767" }, { "nct_id": "NCT03785964", "title": "Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Desmoid Tumor", "Aggressive Fibromatosis" ], "interventions": [ { "name": "Nirogacestat oral tablet", "type": "DRUG" }, { "name": "Placebo Oral Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 142, "start_date": "2019-04-17", "completion_date": "2024-10-17", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 34, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 27 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03785964" }, { "nct_id": "NCT00481832", "title": "Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "BCNU", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Antithymocyte globulin", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Autologous hematopoietic stem cell transplantation (auto-HSCT)", "type": "PROCEDURE" }, { "name": "Allogeneic hematopoietic stem cell transplantation (allo-HSCT)", "type": "PROCEDURE" }, { "name": "Total lymphoid irradiation", "type": "PROCEDURE" }, { "name": "CD34+ Cells", "type": "DRUG" }, { "name": "Solu-Medrol", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 50, "start_date": "2007-01", "completion_date": "2017-03-30", "has_results": true, "last_update_posted_date": "2018-02-14", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00481832" }, { "nct_id": "NCT00006487", "title": "S0004: Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Limited-stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "tirapazamine", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2000-10", "completion_date": "2004-07", "has_results": false, "last_update_posted_date": "2012-10-04", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 87, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006487" }, { "nct_id": "NCT01471509", "title": "Protein, Amino Acids & Insulin & Glucagon Secretion in Humans", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Type 2 Diabetes", "Metabolic Syndrome" ], "interventions": [ { "name": "water, glucose with or without amino acid", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Minneapolis Veterans Affairs Medical Center", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 300, "start_date": "1982-08", "completion_date": "2017-11-06", "has_results": false, "last_update_posted_date": "2017-11-08", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01471509" }, { "nct_id": "NCT03195400", "title": "Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "IGT - Impaired Glucose Tolerance", "T2D" ], "interventions": [ { "name": "Oral Glucose Tolerance Test", "type": "DIAGNOSTIC_TEST" }, { "name": "Hyperglycemic Clamp", "type": "DIAGNOSTIC_TEST" }, { "name": "Isoglycemic Intravenous Glucose Test", "type": "DIAGNOSTIC_TEST" }, { "name": "Hyperinsulinemic Euglycemic Clamp and 2H20", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "12 Years to 18 Years" }, "enrollment_count": 100, "start_date": "2017-03-01", "completion_date": "2022-08-12", "has_results": false, "last_update_posted_date": "2023-02-23", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03195400" }, { "nct_id": "NCT00887536", "title": "A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "doxorubicin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 1613, "start_date": "2009-05", "completion_date": "2018-02", "has_results": false, "last_update_posted_date": "2022-04-20", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 522, "location_summary": "Bessemer, Alabama • Birmingham, Alabama • Huntsville, Alabama + 372 more", "locations": [ { "city": "Bessemer", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00887536" }, { "nct_id": "NCT01464593", "title": "Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colon Cancer Liver Metastasis" ], "interventions": [ { "name": "Lyso-Thermosensitive Liposomal Doxorubicin", "type": "DRUG" }, { "name": "5% Dextrose Solution", "type": "OTHER" }, { "name": "ThermoDox", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Imunon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2011-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2022-10-13", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 4, "location_summary": "Los Angeles, California • The Bronx, New York • Cleveland, Ohio + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01464593" }, { "nct_id": "NCT00928200", "title": "Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Acute Lymphoblastic Leukemia", "Allergy to PEG e.Coli Asparaginase", "Allergy to Native e.Coli Asparaginase" ], "interventions": [ { "name": "Erwinase", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Triple Intrathecal Therapy", "type": "DRUG" }, { "name": "Dexrazoxane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 1, "start_date": "2009-04-13", "completion_date": "2010-06-04", "has_results": true, "last_update_posted_date": "2019-02-19", "last_synced_at": "2026-10-06T13:30:32.611Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00928200" } ] }